Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus | Arthritis Research & Therapy | Full Text
Table 1 from Anti-nucleosome antibodies in patients with systemic lupus erythematosus: potential utility as a diagnostic tool and disease activity marker and its comparison with anti-dsDNA antibody. | Semantic Scholar
Clinical disease activity and flare in SLE: Current concepts and novel biomarkers - ScienceDirect
Lupus flareups cut in half by just 2,000 IU of vitamin D – RCT Dec 2012 | VitaminDWiki
PDF] Biomarkers for Lupus Nephritis: A Critical Appraisal | Semantic Scholar
New insights into the role of antinuclear antibodies in systemic lupus erythematosus | Nature Reviews Rheumatology
Predictive value of autoantibodies for activity of systemic lupus erythematosus
Frontiers | Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus
Novel biomarkers in diagnosis of SLE [11] Biomarker Used As marker of... | Download Table
Managing Pain in Active or Well-Controlled Systemic Lupus Erythematosus
PDF] Predictors of outcome and immunological markers in patients with Systemic lupus erythematosus | Semantic Scholar
Cureus | The Shifting Landscape of Lupus Nephritis Management: A Review
Biomarkers of Disease Activity | Musculoskeletal Key
PDF] Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new. | Semantic Scholar
AVISE SLE Monitor is a Test For the Disease Activity of Lupus
Utility of serum ferritin and soluble interleukin-2 receptor as markers of disease activity in childhood systemic lupus erythematosus. - Abstract - Europe PMC
IJMS | Free Full-Text | Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus
Towards a practical management of fatigue in systemic lupus erythematosus | Lupus Science & Medicine
Biomolecules | Free Full-Text | Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus
Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus - ACR Meeting Abstracts
Systemic Lupus Erythematosus (SLE) - Cancer Therapy Advisor
Hypophosphatemia and Hyponatremia in Systemic Lupus Erythematosus Patients and Its Relation to Clinical Characteristic and Dise